China’s NMPA Approves First CAR T-Cell Therapy for CLDN18.-2+, HER2– Advanced Gastric/GEJ Adenocarcinoma

China’s NMPA Approves First CAR T-Cell Therapy for CLDN18.-2+, HER2– Advanced Gastric/GEJ Adenocarcinoma | OncLive — Onclive

China’s NMPA Approves First CAR T-Cell Therapy for CLDN18.-2+, HER2– Advanced Gastric/GEJ Adenocarcinoma | OncLive